Since the first transcatheter heart valve (TAVR) was performed over 20 years ago, there have been tremendous advances in therapeutic modalities and technologies for valvular heart disease. And the eligible populations, which were limited to those who were either prohibitive or high surgical risk, have broadened. We have seen a paradigm shift in the management of valvular disease and TAVR has gained substantial popularity, especially since it has exhibited high rates of procedural success and low rates of peri-procedural complications.

As innovation and technology advance and research evolves, patients with valvular heart disease are being offered less invasive interventions.

Listen in on industry experts for this Corazon-moderated interview with Dr. Brian Hummel, a Board Certified Cardiothoracic Surgeon, and Bart Berndt, Executive Director of Surgery and Cardiology, as we discuss current indications and limitations on the management of valvular heart disease including:

• What’s new from the 2020 ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the ACC/AHA Joint Committee on Clinical Practice Guidelines
• Developing a high-level strategic plan for determining market and patient potential, including the determination of realistic expectations for volume opportunity while considering patient selection and appropriateness
• More granular details of planning that include economic analysis and the cost/benefit/risks of TAVR versus SAVR and what this means for the hospital
• How to assure clinical quality and operational efficiencies
• And More!

Corazon is the national leader in service line development for the heart, vascular, neuroscience, orthopedic, and perioperative specialties. Contact the Service Line Experts today and stay up-to-date with us on LinkedIn!